Landos Biopharma Dividendes et rachats

Dividende contrôle des critères 0/6

Landos Biopharma n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

23.3%

Rendement des rachats

Rendement total pour l'actionnaire	23.3%
Rendement futur des dividendes	n/a
Croissance des dividendes	n/a
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Ratio de distribution	n/a

Mises à jour récentes sur les dividendes et les rachats

Pas de mise à jour

Recent updates

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de LABP ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de LABP ont augmenté.

Rendement des dividendes par rapport au marché

Landos Biopharma Rendement des dividendes par rapport au marché

Comment le rendement du dividende de LABP se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (LABP)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Pharmaceuticals)	2.4%
Analyste prévisionnel (LABP) (jusqu'à 3 ans)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de LABP par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de LABP par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de LABP afin de déterminer si les dividendes versés sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car LABP n'a signalé aucun versement.

Landos Biopharma Dividendes et rachats

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes sur les dividendes et les rachats

Recent updates

Landos Biopharma Files Form 15

Landos Biopharma, Inc. Announces Board and Executive Changes

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

New minor risk - Share price stability

Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting

Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023

Price target decreased by 52% to US$5.00

Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee

Price target decreased by 48% to US$0.55

Price target decreased by 48% to US$0.55

Price target increased by 82% to US$2.00

Landos Biopharma, Inc. announced that it expects to receive $16.690909 million in funding from Perceptive Advisors LLC

Nasdaq Grants Landos Biopharma an Additional 180-Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Price Requirement

Price target decreased to US$1.10

High number of new and inexperienced directors

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Landos Biopharma, Inc. Reports Positive Top-Line Results from NX-13 Phase 1B Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell 2000 Growth Index

Landos Biopharma, Inc. Names Gregory Oakes as Chief Executive Officer

Landos Biopharma Receives Non-Compliance Letter from Nasdaq

Landos Biopharma, Inc. Announces Executive Changes

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Price target decreased to US$18.82

High number of new and inexperienced directors

Roderick Wong Not Stand for Re-Election as Director of the Landos Biopharma, Inc

Price target decreased to US$18.82

Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc. Is No Longer with the Company

High number of new and inexperienced directors

Insider notifies of intention to sell stock

Insider recently sold US$456k worth of stock

Insider recently sold US$645k worth of stock

Insider recently sold US$364k worth of stock

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Independent Director Konstantin Poukalov has left the company

Landos Biopharma’S Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation At the United European Gastroenterology Week 2021

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell Microcap Value Index

Landos Biopharma, Inc. Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis Patients

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Landos Biopharma (LABP) Investor Presentation - Slideshow

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos Biopharma Announces Positive Results from A Phase 1 Study of NX-13 in Healthy Volunteers

Landos Biopharma, Inc. has completed an IPO in the amount of $100 million.

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés